Detecting residual disease after neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: prospective multicentre preSINO trial
British Journal of Surgery · 01.02.2025 · 112 (2)
DOI: 10.1093/bjs/znaf004 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Surgery, online erschienen am 13.02.2025. Verfasst von Yang Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Neoplasm, Residual, Neoadjuvant Therapy, Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Program of Shanghai Academic/Technology Research Leader.
Abstract (Originalsprache)
Background
Neoadjuvant chemoradiotherapy (nCRT) in patients with oesophageal squamous cell carcinoma (OSCC) may lead to clinical complete response (cCR). It is important to know the accuracy of clinical response evaluations (CREs) before advocating active surveillance instead of oesophagectomy.
Methods
This was a prospective, multicentre study of patients with locally advanced OSCC. They received the first CRE (bite-on-bite biopsies) 4–6 weeks after nCRT. Patients with residual tumour underwent surgery. Patients with a cCR at CRE-1 underwent a second CRE 10–12 weeks after nCRT using PET-CT, bite-on-bite biopsies and endoscopic ultrasound fine-needle aspiration (EUS-FNA). All patients without distant metastases underwent surgery. Primary endpoint was the accuracy of CREs for detecting Tumour Regression Grade (TRG)3–4 or TRG1–2 with ypN+ residual tumour with a prespecified false-negative rate (FNR) of 19.5%. Circulating-tumour DNA (ctDNA) at CREs was performed for exploratory analysis.
Results
In total 309 patients were included. Eighteen of 133 patients with TRG3–4 or TRG1–2 with ypN+ residual tumours were not detected by bite-on-bite biopsies and EUS-FNA (FNR: 13.5%). Sensitivity, specificity, negative predictive value and positive predictive value of detecting any residual tumour were 81.7%, 93.2%, 68.7% and 96.5% respectively. PET-CT detected interval distant metastases in 13 (4.9%) of 268 patients presurgically. After a minimum 12-month follow-up, systemic recurrence rates were 28.0% in patients with positive ctDNA at CREs and 5.3% in those with negative ctDNA.
Conclusions
Bite-on-bite biopsies and EUS-FNA were accurate in detecting residual disease after nCRT in OSCC. Positive ctDNA at CREs may indicate an increased risk of systemic metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Surgery, LKS Faculty of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
- Division of Thoracic Surgery, Chang Gung Memorial Hospital-Linkou, Chang Gung University, Taoyuan, Taiwan, China.
- Department of Surgery, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Rotterdam, The Netherlands.
- Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Zhichao Liu, Ian Wong, Xing Gao, Ben M Eyck, Berend J van der Wilk, Simon Law, Bas P L Wijnhoven
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Program of Shanghai Academic/Technology Research Leader
- Shanghai Chest Hospital Project of Collaborative Innovation
Zitieren
APA
Yang, Y., Liu, Z., Wong, I., Gao, X., Zhang, H., Liu, J., Eyck, B. M., Shao, J., Han, Y., van der Wilk, B. J., Chao, Y., Law, S., Wijnhoven, B. P. L., van Lanschot, J. J. B., & Li, Z. (2025). Detecting residual disease after neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: prospective multicentre preSINO trial. British Journal of Surgery, 112(2). https://doi.org/10.1093/bjs/znaf004
Vancouver
Yang Y, Liu Z, Wong I, Gao X, Zhang H, Liu J, et al. Detecting residual disease after neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: prospective multicentre preSINO trial. British Journal of Surgery. 2025;112(2). doi:10.1093/bjs/znaf004
BibTeX
@article{Yang2025,
author = {Yang, Yang and Liu, Zhichao and Wong, Ian and Gao, Xing and Zhang, Hong and Liu, Jun and Eyck, Ben M and Shao, Jinchen and Han, Yuchen and van der Wilk, Berend J and Chao, Yinkai and Law, Simon and Wijnhoven, Bas P L and van Lanschot, J Jan B and Li, Zhigang},
title = {Detecting residual disease after neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: prospective multicentre preSINO trial},
journal = {British Journal of Surgery},
year = {2025},
volume = {112},
number = {2},
doi = {10.1093/bjs/znaf004}
}
EUVIMED